|
16 May 2023 |
Celldex Therapeutics Presents Positive Preclinical Data from TSLP/SCF Bispecific Antibody Program CDX-622 at IMMUNOLOGY2023™
|
|
16 May 2023 |
Sony and Astellas Enter into Collaborative Research Agreement to Discover a Novel ADC Platform for the Oncology Field
|
|
15 May 2023 |
Dualyx raises €40 million to progress Treg therapies for autoimmune diseases into the clinic
|
|
15 May 2023 |
BiOneCure Therapeutics and Nanjing Leads Biolabs Join Forces to Develop Innovative Anti-Drug Conjugates (ADCs) for Solid Tumor Treatment
|
|
15 May 2023 |
U.S. Food and Drug Administration Issues Complete Response Letter for Byondis' [Vic-]Trastuzumab Duocarmazine
|
|
15 May 2023 |
Therini Bio Initiates First-In-Human Dosing in Phase 1 Trial of THN391, a Fibrin-Targeting Therapeutic Candidate for Alzheimer’s Disease
|
|
15 May 2023 |
Numab Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of NM26 Program
|
|
13 May 2023 |
LaNova Medicines Announces Global Exclusive License Agreement with AstraZeneca for LM-305, a Novel GPRC5D-Targeting Antibody Drug Conjugate
|
|
12 May 2023 |
Results of Phase I Clinical Study of Qilu Pharma's PD-1/CTLA-4 Bifunctional Antibody Iparomlimab/Tuvonralimab Published Online in Journal of Hematology & Oncology
|
|
10 May 2023 |
Ultomiris approved in the EU for adults with neuromyelitis optica spectrum disorder (NMOSD)
|
|
10 May 2023 |
Sandoz strengthens pipeline expansion through partnership to develop and manufacture multiple biosimilars
|
|
10 May 2023 |
Lassen Therapeutics Announces Oral Presentation of Phase I Data of LASN01, an IL-11 Receptor-Blocking Antibody for Treatment of Pulmonary Fibrosis, at the American Thoracic Society 2023 Annual Meeting
|
|
10 May 2023 |
Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases
|
|
10 May 2023 |
Summit Therapeutics Announces First Patient Treated in Phase III HARMONi Clinical Trial Evaluating Ivonescimab (SMT112)
|
|
09 May 2023 |
Arxx Therapeutics initiates first-in-human trial of AX-202 – a monoclonal antibody under development for fibrotic diseases
|
|
09 May 2023 |
ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer’s Disease
|
|
09 May 2023 |
FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics
|
|
09 May 2023 |
Biosion Presents Discovery and Development Data at PEGS for its Anti-CD40 Agonistic Antibody
|
|
09 May 2023 |
Innovent Announces First Participant Dosed in Phase 3 Study (RESTORE) of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Eye Disease
|
|
09 May 2023 |
Hummingbird Bioscience to Present Preclinical Proof of Concept for Potentially First-In-Class Antibody Targeting Autoimmune Diseases
|
|
09 May 2023 |
FDA Accepts Application for Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)
|
|
08 May 2023 |
Eisai enters into joint development agreement with BlissBio for antibody drug conjugate BB-1701 with option rights for strategic collaboration
|
|
05 May 2023 |
Trellis Bioscience Announces Positive Interim Phase 1 Results for TRL1068, a Novel Native Human Monoclonal Antibody Which Reduces Bacterial Biofilm Burden in Chronic Prosthetic Joint Infections
|
|
05 May 2023 |
Alvotech Initiates Confirmatory Patient Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
|
|
05 May 2023 |
Tonix Pharmaceuticals Announces IND Clearance for TNX-1500 (anti-CD40L mAb) for the Prevention of Organ Rejection in Patients Receiving a Kidney Transplant
|
